PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2019
CASE
AUTH/3232/7/19 Boehringer Ingelheim

AUTH/3232/7/19 & AUTH/3233/7/19: Public complaint about POM congress stand visibility (No breach)

A member of the public alleged POM promotional panels at ExCeL London were visible/readable from a public coffee area. Panel found the…

2010
CASE
AUTH/2351/8/10 Roche Products

AUTH/2351/8/10: Lilly v Roche – Promotion of Tarceva and the meaning of β€œfirst-line maintenance” (No breach on appeal)

Lilly challenged Roche’s use of β€œfirst-line maintenance” for Tarceva across a leavepiece, ad and sponsored feature. Panel found breaches, but the Appeal…

2008
CASE
Sanofi ⭐ Case of the Week

Sanofi-Aventis: HSJ β€˜special report’ found to be disguised promotion for dronedarone (Clause 12.1)

A sponsored HSJ β€˜special report’ on atrial fibrillation looked like independent editorial and favoured dronedarone. PMCPA ruled Sanofi-Aventis was inextricably linked to…

2011
CASE
AUTH/2397/4/11 Warner Chilcott

Hospital consultant v Warner Chilcott: Asacol leavepiece claim β€œup to 72% treatment success” (AUTH/2397/4/11)

A consultant challenged an Asacol leavepiece claiming β€œup to 72% treatment success”. The Panel found breaches, but on appeal the Appeal Board…

2011
CASE
AUTH/2389/2/11 Alcon Laboratories

AUTH/2389/2/11: Allergan v Alcon β€” Travatan β€œthornless rose” visual and lab-data tolerability claims

Alcon’s Travatan BAK-free ad used a thornless rose and animal/in vitro data implying better tolerability vs BAK formulation. PMCPA found the ad…

2018
CASE
AUTH/3088/9/18 Ipsen

AUTH/3088/9/18: Director v Ipsen (Clinical trial disclosure) – No breach

BMJ analysis suggested 3 Ipsen trials were missing EUCTR results. Panel found 2 trials had no UK nexus and 1 was cancelled…

2008
CASE
Abbott Laboratories

Abbott voluntary admission: representative worked without passing ABPI Medical Representatives Examination (Clause 16.3)

Abbott disclosed that one representative had not taken/passed the ABPI Medical Representatives Examination after exemptions ended in 2006. PMCPA ruled a breach…

2008
CASE
AstraZeneca ⭐ Case of the Week

AstraZeneca & Bristol-Myers Squibb: Onglyza advert in Health Service Journal (audience targeting) – no breach on appeal

Two public complaints said an Onglyza advertorial in Health Service Journal was inappropriate/too technical and potentially public-facing. Panel found a Clause 11.1…

2018
CASE
AUTH/3117/11/18 Seqirus

AUTH/3117/11/18: Director v Seqirus (Clinical trial disclosure) – Outwith scope of the Code

PMCPA case AUTH/3117/11/18 (Director v Seqirus) concerned clinical trial disclosure but was ruled outwith the scope of the ABPI Code (2016). No…

2019
CASE
AUTH/3236/8/19 Merck Sharp & Dohme

AUTH/3236/8/19: Health professional v Merck Sharp & Dohme – incorrect Disclosure UK transfer of value entry

A health professional challenged an incorrect Disclosure UK entry showing MSD provided financial support. The Panel found the disclosure inaccurate and misleading,…

2019
CASE
Gilead Sciences Europe

Gilead ruled in breach for failing to comply with an undertaking: Biktarvy tolerability claim remained on website

ViiV and the PMCPA Director complained that Gilead continued to display a Biktarvy tolerability claim on a UK-accessible website after giving an…

2019
CASE
Allergan

Allergan: Botox pack shots and award reposts on Instagram found to promote a POM to the public

Allergan reposted Instagram Stories and employee posts that included Botox pack shots and an β€œInjectable Product of the Year” reference. The Panel…

2019
CASE
AUTH/3285/12/19 Daiichi-Sankyo UK

AUTH/3285/12/19: Ex-employee v Daiichi-Sankyo – Underreporting transfers of value on Disclosure UK

An ex-employee alleged Daiichi-Sankyo grossly underreported conference-related transfers of value on Disclosure UK (2016–2018). The Panel found multiple disclosure and record-keeping breaches,…

2019
CASE
Colonis Pharma ⭐ Case of the Week

Colonis voluntary admission: wrong prescribing information in promotional letter for Melatonin Oral Solution

Colonis admitted a promotional letter for Melatonin 1mg/ml Oral Solution included prescribing information for Melatonin 3mg tablets. The Panel ruled breaches including…

2021
CASE
GlaxoSmithKline ⭐ Case of the Week

GSK breach upheld on taskforce website: sponsorship not clearly acknowledged β€œfrom the outset” (Clause 25.3)

GSK funded a patient-organisation-hosted taskforce. PMCPA found sponsorship disclosure wasn’t clear β€œfrom the outset” because it was only accessible via small footer…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training